James G Krueger Selected Research

ixekizumab

1/2018	Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis.
5/2016	New therapies for psoriasis and psoriatic arthritis.
12/2014	IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood.
1/2014	IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model.
7/2012	IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James G Krueger Research Topics

Disease

168	Psoriasis (Pustulosis Palmaris et Plantaris) 04/2024 - 05/2002
55	Inflammation (Inflammations) 01/2024 - 07/2004
45	Atopic Dermatitis (Atopic Eczema) 03/2024 - 11/2008
20	Skin Diseases (Skin Disease) 05/2024 - 02/2005
19	Hyperplasia 01/2022 - 04/2006
14	Hidradenitis Suppurativa 05/2024 - 01/2018
14	Melanoma (Melanoma, Malignant) 09/2023 - 12/2013
14	Neoplasms (Cancer) 03/2023 - 04/2006
13	Alopecia Areata 01/2023 - 01/2015
8	Atherosclerosis 10/2021 - 01/2012
6	Psoriatic Arthritis 01/2024 - 01/2011
6	Hypersensitivity (Allergy) 06/2023 - 10/2014
6	Neoplasm Metastasis (Metastasis) 03/2023 - 01/2015
6	Autoimmune Diseases (Autoimmune Disease) 01/2019 - 10/2004
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 07/2020 - 04/2006
5	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 07/2010
4	Pruritus (Itching) 01/2023 - 01/2019
4	Infections 01/2018 - 12/2005
3	Necrosis 01/2024 - 03/2013
3	Cicatrix (Scar) 01/2024 - 01/2019
3	Body Weight (Weight, Body) 01/2023 - 05/2016
3	Alopecia (Baldness) 10/2022 - 10/2021
3	Erythema 01/2021 - 03/2012
3	Ichthyosis (Xeroderma) 01/2019 - 01/2017
3	Contact Dermatitis (Eczema, Contact) 03/2015 - 02/2013
3	Rheumatoid Arthritis 03/2010 - 05/2007
2	Disease Progression 03/2024 - 09/2014

Drug/Important Bio-Agent (IBA)

65	CytokinesIBA 01/2024 - 01/2004
53	Interleukin-17 (Interleukin 17)IBA 01/2023 - 05/2008
34	Biomarkers (Surrogate Marker)IBA 03/2024 - 06/2007
34	Proteins (Proteins, Gene)FDA Link 07/2023 - 04/2006
24	Interleukin-23 (Interleukin 23)IBA 01/2023 - 01/2004
20	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 07/2004
17	InterleukinsIBA 01/2024 - 01/2004
13	Interleukin-12 (IL 12)IBA 01/2024 - 02/2003
13	Messenger RNA (mRNA)IBA 07/2023 - 02/2003
12	Interleukin-22 (IL-22)IBA 01/2020 - 11/2008
11	RNA (Ribonucleic Acid)IBA 01/2023 - 01/2012
10	Ustekinumab (CNTO 1275)FDA Link 10/2023 - 08/2011
10	diphenylcyclopropenoneIBA 06/2023 - 10/2014
10	ChemokinesIBA 01/2023 - 07/2004
9	Keratin-16 (Keratin 16)IBA 01/2022 - 05/2002
9	Etanercept (Enbrel)FDA Link 01/2020 - 08/2005
9	efalizumab (Raptiva)FDA Link 01/2012 - 05/2002
8	secukinumabIBA 01/2024 - 05/2016
8	brodalumabIBA 01/2022 - 03/2012
7	dupilumabIBA 01/2023 - 12/2014
6	LigandsIBA 01/2023 - 05/2007
6	Monoclonal AntibodiesIBA 01/2022 - 08/2011
6	InterferonsIBA 01/2021 - 01/2004
6	Filaggrin ProteinsIBA 01/2021 - 01/2017
6	LipidsIBA 01/2021 - 01/2017
6	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2021 - 12/2005
6	AntibodiesIBA 01/2020 - 03/2008
6	tofacitinibIBA 01/2020 - 09/2009
6	Tumor Necrosis Factor InhibitorsIBA 01/2020 - 05/2007
5	Interleukin-13IBA 01/2023 - 10/2017
5	Janus KinasesIBA 01/2022 - 10/2019
5	Interleukin-6 (Interleukin 6)IBA 01/2022 - 01/2018
5	ixekizumabIBA 01/2018 - 07/2012
5	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2017 - 02/2008
5	Alefacept (Amevive)FDA Link 02/2010 - 02/2005
4	HaptensIBA 06/2023 - 10/2014
4	Blood Proteins (Serum Proteins)IBA 01/2022 - 01/2014
4	Interleukin-10 (Interleukin 10)IBA 11/2021 - 10/2007
4	loricrinIBA 01/2021 - 01/2019
4	Adalimumab (Humira)FDA Link 05/2020 - 08/2015
4	Interleukin-8 (Interleukin 8)IBA 01/2020 - 08/2005
4	risankizumabIBA 01/2019 - 07/2015
4	Immunoglobulin E (IgE)IBA 01/2019 - 11/2015
4	apremilastIBA 08/2018 - 08/2013
4	AntigensIBA 01/2018 - 09/2011
3	spesolimabIBA 04/2024 - 01/2022
3	Immunologic Factors (Immunomodulators)IBA 03/2024 - 08/2015
3	Immunomodulating AgentsIBA 01/2024 - 07/2010
3	Immune Checkpoint InhibitorsIBA 03/2023 - 01/2016
3	pneumococcal purpura-producing principle (PPPP)IBA 01/2023 - 01/2016
3	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2023 - 01/2013
3	AllergensIBA 01/2023 - 08/2014
3	guselkumabIBA 01/2023 - 04/2014
3	SaltsIBA 10/2022 - 10/2021
3	Janus Kinase InhibitorsIBA 01/2022 - 05/2016
3	Lipocalin-2IBA 01/2022 - 11/2008
3	EnzymesIBA 11/2021 - 01/2016
3	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021 - 03/2002
3	Interleukin-17 ReceptorsIBA 01/2020 - 06/2011
3	Interleukin-4 (Interleukin 4)IBA 01/2019 - 10/2007
3	6-sulfo sialyl Lewis XIBA 01/2019 - 10/2015
2	Abatacept (Orencia)FDA Link 10/2023 - 11/2021
2	Phosphotransferases (Kinase)IBA 09/2023 - 01/2018
2	NickelIBA 01/2023 - 08/2014
2	pembrolizumabIBA 12/2022 - 04/2017
2	ProteomeIBA 01/2022 - 01/2021
2	TYK2 Kinase (Tyrosine Kinase 2)IBA 01/2022 - 01/2022
2	deucravacitinibIBA 01/2022 - 01/2022

Therapy/Procedure

44	Therapeutics 04/2024 - 02/2003
6	Lasers (Laser) 09/2023 - 01/2011
5	Biological Therapy 01/2019 - 08/2005
4	Immunotherapy 03/2023 - 02/2005
4	Aftercare (After-Treatment) 01/2023 - 11/2020